Clinical trials: Bronchopulmonary Dysplasia
Respiratory Syncytial Virus (RSV)
A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus
This is a Phase 3b, prospective, multicenter, open-label, non-controlled study to assess the safety and effectiveness of immunoprophylaxis with the intramuscular (IM) administration of the liquid formulation of palivizumab for…
- Trial name
- Synagis Russia (NCT02968173)
- Testing
- Palivizumab
- Volunteers
- 50 people
- Sponsor
- AbbVie
Ventilator Lung; Newborn
Comparing Intubation Rates in the Delivery Room by Interface
Although the majority of premature neonates < 30 weeks gestion require positive pressure ventilation (PPV) at birth, the optimal interface to provide PPV has not been determined.
- Trial name
- NCT05609773
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Illinois College of Medicine at Peoria
Pulmonary Hypertension, Bronchopulmonary Dysplasia
The Role of Transthoracic Echocardiography in Diagnosis of Pulmonary Hypertension of Infants With Bronchopulmonary Dysplasia
Pulmonary hypertension may develop in premature newborn infants due to impaired lung development. The diagnosis of this disease can actually be made with interventional methods.
- Trial name
- NCT05082272
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Kayseri City Hospital
Newborn Morbidity, Respiratory Failure
Comparing Two Different Modes of Ventilation in Pretem Neonates Bilevel VG and PRVC
Intubated preterm infants between 800-1200 grams and under 32 weeks of gestational age will start with PRVC ventilation mode, basal blood gases and work of breathing will measured.
- Conditions
- Newborn Morbidity, Respiratory Failure, Bronchopulmonary Dysplasia, Mechanical Ventilation Complication
- Trial name
- NCT04191239
- Testing
- GE ventilator with two different modes
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Ankara City Hospital Bilkent
Bronchopulmonary Dysplasia, Chronic Lung Disease
Neurotrophin Expression in Infants as a Predictor of Respiratory and Neurodevelopmental Outcomes
Important developmental processes continue until the completion of 40 weeks gestation. Even during fetal life, intrinsic and environmental factors determine the balance between health and the onset and development of diseases.
- Trial name
- NCT03373539
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- The Cleveland Clinic
Bacteria Infection, Respiratory Tract Infections
Early Versus Expectant Treatment of Ureaplasma Infection in Very Low Birth Weight Neonates
Our hypothesis is that treatment of known Ureaplasma spp. infection of the airways in very low birth weight (VLBW) infants with azithromycin will eradicate the organisms and lessen the proinflammatory state caused by infection…
- Trial name
- NCT00599053
- Testing
- Azithromycin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Alabama at Birmingham
Infant, Newborn, Infant, Low Birth Weight
Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)
This pilot study is a randomized, placebo-controlled, clinical trial to measure changes in blood and urine levels of inositol in premature infants at high risk for retinopathy of prematurity (ROP) following repeated doses of…
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
- Trial name
- INS-2 (NCT01030575)
- Testing
- Inositol lower volume, Inositol mid-level volume, Inositol high volume
- Where
- 17 sites in United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- NICHD Neonatal Research Network
Bronchopulmonary Dysplasia
Pulmonary MRI of Ex-preterm Children With and Without BPD To Understand Risk of Emphysematous Changes
Health Issue: Bronchopulmonary dysplasia (BPD), a chronic lung disease, is the most common complication of being born premature. Damage to the still developing lung stops the normal formation of the alveoli.
- Trial name
- PICTURE (NCT02921308)
- Where
- 4 sites in Canada
- Volunteers
- 45 people
- Sponsor
- Children's Hospital of Eastern Ontario
Bronchopulmonary Dysplasia (BPD), Premature Births
PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia
The purpose of the study is to learn how safe montelukast may be in premature infants at significant risk for Bronchopulmonary Dysplasia (BPD) and to determine how much and how quickly montelukast moves from the stomach into the…
- Conditions
- Bronchopulmonary Dysplasia (BPD), Premature Births, Critical Illness
- Trial name
- PRISM (NCT07101640)
- Testing
- montelukast 4 mg granule
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Duke University
Infant, Newborn, Diseases, Other Preterm Infants
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
This study compared the use of continuous positive airway pressure initiated at birth with the early administration of surfactant administered through a tube in the windpipe within 1 hour of birth for premature infants born at 24…
- Conditions
- Infant, Newborn, Diseases, Other Preterm Infants, Infant, Small for Gestational Age, Premature Birth
- Trial name
- SUPPORT (NCT00233324)
- Testing
- Surfactant, Continuous Positive Airway Pressure (CPAP), Supplemental oxygen with target saturation of 85 to 89%
- Where
- 22 sites in United States
- Volunteers
- 1,316 people
- Sponsor
- NICHD Neonatal Research Network
Bronchopulmonary Dysplasia
Effect of Caffeine Versus Probiotic on Preterm Neonates With Bronchopulmonary Dysplasia
The aim of this study is to evaluate the effectiveness of caffeine versus probiotics supplementation as adjuvant therapy for preterm neonates with Bronchopulmonary dysplasia (BPD).
- Trial name
- NCT05682807
- Testing
- Caffeine, Probiotic Formula
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Tanta University
Respiratory Tract Diseases
Budesonia + Intratracheal Surfactant in Incidence of Bronchopulmonary Dysplasia
Objectiv: To compare the effect of intratracheal administration of surfactant vs. surfactant/budesonide on the incidence of bronchopulmonary dysplasia in preterm infants less than 34 weeks of gestation.
- Trial name
- NCT05534685
- Testing
- intratracheal administration of surfactant/budesonide, incidence of bronchopulmonary dysplasia
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Bronchopulmonary Dysplasia
The Role of Volatile Organic Compounds (VOCs), Airway Mucins and the Microbiome in the Early Prediction of Bronchopulmonary Dysplasia (BPD)
Bronchopulmonary dysplasia (BPD), the most common respiratory complication of extremely preterm birth, significantly impacts healthcare with high morbidity and mortality rates.
- Trial name
- INFANCY (NCT06342752)
- Testing
- Breath test, Throat swabs, Placental samples
- Where
- Belgium
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University Hospital, Antwerp
Bronchopulmonary Dysplasia, Premature
THE EFFECT OF NEBULIZED AZITHROMYCIN AS THERAPY FOR BRONCHOPULMONARY DYSPLASIA
The aim of the study is to determine the effectiveness of nebulized azithromycin therapy in prevention of BPD in very low birth weight preterm infants when compared with placebo.
- Conditions
- Bronchopulmonary Dysplasia, Premature, Ventilation, Mechanical
- Trial name
- NCT06584474
- Testing
- Azithromycin neubilization, Lung ultrasound
- Where
- 2 sites in Egypt
- Volunteers
- 100 people
- Sponsor
- Alexandria University
Bronchopulmonary Dysplasia
Preservation of Blood in Extremely Preterm Infants
Current clinical protocols for blood sampling and analyses in extremely preterm infants rely on an infrastructure adapted to and developed for adult medicine.
- Trial name
- LIM (NCT04239690)
- Testing
- Micromethods for blood sample analysis
- Where
- Sweden
- Volunteers
- 201 people
- Sponsor
- David Ley
Premature Birth, Obstructive Lung Disease
Pulmonary Outcomes of Bronchopulmonary Dysplasia in Young Adulthood
Preterm birth alters the normal sequence of lung development with lasting respiratory consequences. It is still unclear whether observed respiratory morbidities in preterm born individuals reflect sequelae from a non-progressive…
- Conditions
- Premature Birth, Obstructive Lung Disease, Bronchopulmonary Dysplasia
- Trial name
- NCT02820818
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- St. Justine's Hospital
Bronchopulmonary Dysplasia
Follow-Up Study of Mesenchymal Stem Cells for Bronchopulmonary Dysplasia
This is a follow-up study to investigate the long-term safety and efficacy of human umbilical cord -derived mesenchymal stem cells (hUC-MSCs), for the treatment of BPD in premature infants.
- Trial name
- NCT03873506
- Testing
- transplantation of hUC-MSCs
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Children's Hospital of Chongqing Medical University
Bronchopulmonary Dysplasia, Patent Ductus Arteriosus
MISA to NRDS：a Multicenter Study in China
BACKGROUND Treatment of neonatal respiratory distress syndrome with exogenous surfactant and mechanical ventilation made millions of preterm infants survived in neonatal intensive care unit (NICU).
- Conditions
- Bronchopulmonary Dysplasia, Patent Ductus Arteriosus, Intraventricular Hemorrhage, Necrotizing Enterocolitis
- Trial name
- NCT04077333
- Testing
- Minimal Invasive surfactant administration
- Where
- China
- Volunteers
- 237 people
- Sponsor
- Peking University Third Hospital
Bronchopulmonary Dysplasia, Prematurity
Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia
The purpose of this study is to identify biological markers that might predict premature infants who are at a higher risk for developing BPD, and to correlate the presence of these markers with infant symptoms and lung function…
- Trial name
- GRP (NCT01748565)
- Where
- 2 sites in United States
- Volunteers
- 260 people
- Sponsor
- Duke University
Bronchopulmonary Dysplasia
Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)
This is a randomized, parallel-group, double-blind, placebo-controlled multicenter phase 2b/3 study with an adaptive seamless design.
- Trial name
- ZELA (NCT06897839)
- Testing
- Zelpultide alfa
- Where
- 49 sites in Argentina, Belgium and 6 more
- Volunteers
- 366 people
- Sponsor
- Airway Therapeutics, Inc.